Indivior Pharmaceuticals 3Q 2026: Revenue $356M, EPS $1.12— 10-Q Summary
Indivior Pharmaceuticals reported Q3 2026 revenue of $356M, up 13.4% YoY, and net income of $137M, up 226.2%. EPS rose to $1.12. Growth was driven by SUBLOCADE sales, which accounted for 75% of revenue. The company plans to sell its French and German SUBUTEX tablet business.
How this was made
The 30-second read
Why it matters
Near-term trading focus is likely on the magnitude of revenue and EPS improvement and whether SUBLOCADE growth can sustain. Medium-term focus is on execution of OPVEE marketing discontinuation, planned SUBUTEX tablet business sale in France and Germany, and the 2027 manufacturing provider transition plus Rest of World revenue optimization.
Market read
This is a company-specific quarterly disclosure with concrete financial metrics and operational actions that can change near-term earnings expectations and medium-term revenue risk.
What to watch
No detail is provided on margins, cash flow, or the financial impact/timing of the French and German SUBUTEX tablet business sale, which could be material for valuation.
Background
The piece summarizes Indivior’s Oct. 29, 2026 10-Q for 3Q 2026, including financial results and several business actions affecting its OUD product portfolio.
Ticker impact
Indivior reported 3Q 2026 net revenue of $356M and diluted EPS of $1.12, plus SUBLOCADE growth and plans to sell SUBUTEX tablet businesses.
Likely upward bias as investors price in stronger SUBLOCADE momentum and higher earnings, partially offset by uncertainty around the 2027 manufacturing transition and Rest of World revenue optimization.
The article provides concrete quarterly financials and specific business actions (discontinuation and planned divestiture), which can move near-term expectations, but it lacks guidance or detailed cost/transition assumptions.
Market effects
Highlights ongoing demand strength in opioid-use-disorder branded therapies (SUBLOCADE) and the operational reshaping of product portfolios.
Rest of World optimization is expected to reduce future revenue, which may shift regional growth expectations for branded OUD franchises.
Limited broader market relevance beyond specialty pharma sentiment, unless peers react to similar product mix and manufacturing-transition risks.
Counterpoint
The headline earnings improvement may be partly mix-driven (SUBLOCADE concentration) while future revenue could be pressured by Rest of World optimization and the 2027 manufacturing provider transition.
Key entities
- companyIndivior Pharmaceuticals, Inc.
Reported 3Q 2026 net revenue $356M and diluted EPS $1.12, with SUBLOCADE growth and planned portfolio changes including SUBUTEX tablet business sale plans.
- productSUBLOCADE
Indivior’s product whose global sales grew 22% in the quarter, accounting for 75% of quarterly revenue.
- productOPVEE
Indivior discontinued OPVEE marketing as part of its business actions.
- productSUBUTEX
Indivior plans to sell its French and German SUBUTEX tablet business; manufacturing transition expected in 2027.
